**3. Repurposing in Zikv virus and other Flaviviruses infection**

It was a mosquito-borne flavivirus, associated with several birth defects which are associated with infant neurological disorder (Gullain-Barre syndrome and other) and severe congenital defects in Newbern (microcephaly and ophthalmological alteration) such infection occurs during pregnancy. These viruses are capable of spreading both vertical (transplacental) and sexual, this infection is prime concerned for globule and public health, neither specific antiviral treatment nor a vaccine to counteract ZIKV diffusion is available to date. Henceforth FDA-approved drug repurposing camping started by WHO.

The library of 774 FDA-approved immunosuppressant drugs candidates were tested on HuH-7 hepatocytes cell-cultured strains isolated from ZIKV, among which 24 candidates showed potent anti-ZIKV activity which inhibits the ZIKV replication,

#### **Drugs:**


#### **3.1 Repurposing in Ebola virus infection**

EBOV was discovered in the late 1970s but the outbreak was in 2014-2016 was an alarming period due to its size and spread, the cases were reported internationally in

